arrow
M

Markus Dietlein

University of Cologne
H指数:50
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Auger-Emitting Radionuclides in Radiopharmaceutical Research: Decay-Associated Processes, Vector-Dependent Localization, and Translational Perspectives

俄歇发射放射性核素在放射性药物研究中的应用:衰变相关过程、载体依赖性定位及转化研究视角

2026-08-120
OAAI
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin Lymphoma

对接受治疗的前期经典霍奇金淋巴瘤患者中新引入的Deauville Score 5a评分的验证

2026-07-020
OA
Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy

你知道你的psma-tracer吗?不同PSMA配体的生物分布的变异性及其对PSMA靶向治疗前定义PSMA阳性的潜在影响

2025-01-100
OAAI
Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
2024-12-011
OAAI
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

评估PET引导的BrECADD与eBEACOPP在晚期经典霍奇金淋巴瘤 (HD21) 中的疗效和耐受性: 一项随机,多中心,平行,开放标签的3期试验

LANCET
IF88.5
2024-07-019
OAAI
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

GHSG HD16试验在PET指导下治疗早期有利的霍奇金淋巴瘤的随访

LEUKEMIA
IF13.4
2023-10-164
OAAI
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
2023-01-019
OAAI
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial

基线代谢性肿瘤体积在早期有利的霍奇金淋巴瘤中的预测价值-来自前瞻性,多中心III期HD16试验的数据

2022-06-1821
OAAI